Avexitide has been designated as a breakthrough therapy by the FDA for the treatment of hypoglycemia following obesity treatment and congenital hyperinsulinemia.
Amyrix Pharmaceuticals Acquires Avexitide, a Phase 3 Clinical Trial-Ready GLP-1 Receptor Agonist for the Treatment of Hyperinsulinemic Hypoglycemia, from Eiger Biopharmaceuticals
Leave a comment
